I'm curious about what people think about switching to the 2nd generation TKIs from gleevec.
I should start by saying that I've switched from gleevec to tasigna, mainly for side effects and that switch has been very successful both in terms of side effects and response. I often hear/read talk of resistance and I haven't totally got my head around the difference between resistance say to antibiotics and TKIs. I've also heard people say that with cancer your first strike should be your best effort, which kinda makes sense in my way of thinking - the fewer dodgy cells there are, the smaller the chance of one of them developing a crazy bad mutation. It it that simple?
I was reading this paper: Jorge Cortes and Hagop Kantarjian, How I treat newly diagnosed chronic phase CML, Blood, 2012
Do others have access to this? (I'm inside a university)
I'll try posting a figure from that paper that caught my attention (not sure if it's ok to reproduce the figure, but I hope so...), obviously it is speculative but these authors are well placed to speculate.